Barclays raised the firm’s price target on Roche to CHF 275 from CHF 230 and keeps an Equal Weight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Roche sees 2024 core EPS growing in high single digit range
- Roche reports 1H core EPS CHF 10.23 vs. CHF 10.10 last year
- [Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 5% (CER) in first half of 2024; strong growth in second quarter – full-year earnings outlook raised
- Truist healthcare analyst holds an analyst/industry conference call
- Roche failure removes potential downside for Apellis, says Baird